Abingworth is the famous VC, which was founded in 1973. The fund was located in Europe if to be more exact in United Kingdom. The leading representative office of defined VC is situated in the London.
Besides them, we counted 12 critical employees of this fund in our database.
Among the various public portfolio startups of the fund, we may underline Pharmion, Algeta, Senseonics The fund has exact preference in some founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Life Science, Biopharma.
Speaking about the real fund results, this VC is 3 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2014. Comparing to the other companies, this Abingworth performs on 18 percentage points more the average number of lead investments. The average startup value when the investment from Abingworth is 5-10 millions dollars. The important activity for fund was in 2009. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 deals per year.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Abingworth, startups are often financed by Versant Ventures, SR One, InterWest Partners. The meaningful sponsors for the fund in investment in the same round are Atlas Venture, Wellcome Trust, Frazier Healthcare Partners. In the next rounds fund is usually obtained by MPM Capital, InterWest Partners, Versant Ventures.
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Myricx Pharma | $123M | 08 Jul 2024 | United Kingdom, England, United Kingdom | ||
Entos | $50M | 24 Apr 2024 | Los Angeles, California, United States | ||
Ascend | $65M | 09 May 2023 | - | ||
Pathalys Pharma | $150M | 18 Jan 2023 | Raleigh, North Carolina, United States | ||
Entact Bio | $81M | 06 Dec 2022 | Watertown, Massachusetts, United States | ||
Venatorx Pharmaceuticals | $34M | 04 Apr 2022 | Pennsylvania, United States | ||
Anjarium Biosciences | $60M | 15 Sep 2021 | Schlieren, Zurich, Switzerland | ||
Glycomine | $35M | 23 Jun 2021 | San Francisco, California, United States | ||
Adaptate Biotherapeutics | $17M | 19 Apr 2021 | London, Ontario, Canada |
– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.
– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Myricx Pharma | $123M | 08 Jul 2024 | United Kingdom, England, United Kingdom | ||
Entos | $50M | 24 Apr 2024 | Los Angeles, California, United States | ||
Ascend | $65M | 09 May 2023 | - | ||
Pathalys Pharma | $150M | 18 Jan 2023 | Raleigh, North Carolina, United States | ||
Entact Bio | $81M | 06 Dec 2022 | Watertown, Massachusetts, United States | ||
Venatorx Pharmaceuticals | $34M | 04 Apr 2022 | Pennsylvania, United States | ||
Anjarium Biosciences | $60M | 15 Sep 2021 | Schlieren, Zurich, Switzerland | ||
Glycomine | $35M | 23 Jun 2021 | San Francisco, California, United States | ||
Adaptate Biotherapeutics | $17M | 19 Apr 2021 | London, Ontario, Canada |